LIVZON PHARMA(01513.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 576.91 million, YoY decrease of 9.39%
- LIVZON PHARMA (01513.HK): Leuprorelin 3-Month Formulation Approved
- LIVZON PHARMA (01513.HK): Proposes Appointment of Zhu Linlin as Non-Executive Director of the Twelfth Board
- LIVZON PHARMA (01513.HK): Zhu Baoguo resigns as Chairman on retirement; President Liu Daping appointed
- LIVZON PHARMA (01513.HK): Lecankitug injection approved for marketing; first domestic IL-17A/F dual-target biologic in China
